Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
IUBMB Life. 2018 May;70(5):437-444. doi: 10.1002/iub.1733. Epub 2018 Mar 9.
Prostate cancer (PCa) is considered the most common malignancy in men. The aim of this study is to assess the role of serum miR-15a and miR-16-1 expression in PCa development, diagnosis and prognosis aiming to find a specific noninvasive biomarker. This study comprised 70 patients with PCa, 70 patients complaining of benign prostatic hyperplasia (BPH), 30 patients with chronic prostatitis and 70 controls. Circulating miR-15a and miR-16-1 expression was detected by real-time polymerase chain reaction. Prostate specific antigen levels were measured by enzyme-linked immunosorbent assay. The expression levels of serum miR-15a were decreased in PCa patients compared with controls, chronic prostatitis and BPH patients (0.43 ± 0.12, 1.7 ± 0.76, 1.56 ± 0.34 and 1.53 ± 0.65, respectively). The expression levels of serum miR-16-1 were decreased in PCa patients compared with controls, chronic prostatitis and BPH patients (0.55 ± 0.23, 2.15 ± 0.87, 2.08 ± 0.54 and 1.96 ±0.61, respectively). Downregulation of miR-15a and miR-16-1 correlated with higher Gleason score (P = 0.002 and P = 0.006, respectively), higher tumor stage (P = 0.001 and P = 0.01, respectively), PCa metastasis (P = 0.002 and P = 0.025, respectively) and lymph node involvement (P = 0.02 and P = 0.007, respectively). Moreover, Receiver operating characteristic curve analysis revealed that combined miR-15a/miR-16-1 and PSA increased the sensitivity and specificity for the diagnosis of PCa (97.1% and 94.3%, respectively) more than prostate specific antigen alone (82.9% sensitivity and 75.7% specificity). Combined serum miR-15a/miR-16-1 expression and PSA level can be used as promising specific noninvasive biomarkers in the diagnosis and prognosis of PCa better than prostate specific antigen alone. © 2018 IUBMB Life, 70(5):437-444, 2018.
前列腺癌（PCa）被认为是男性最常见的恶性肿瘤。本研究旨在评估血清 miR-15a 和 miR-16-1 表达在 PCa 发展、诊断和预后中的作用，旨在寻找一种特异性的非侵入性生物标志物。本研究纳入了 70 例 PCa 患者、70 例良性前列腺增生（BPH）患者、30 例慢性前列腺炎患者和 70 例对照组。采用实时聚合酶链反应检测循环 miR-15a 和 miR-16-1 的表达。采用酶联免疫吸附试验检测前列腺特异性抗原（PSA）水平。与对照组、慢性前列腺炎组和 BPH 组相比，PCa 患者血清 miR-15a 的表达水平降低（0.43±0.12、1.7±0.76、1.56±0.34 和 1.53±0.65）。与对照组、慢性前列腺炎组和 BPH 组相比，PCa 患者血清 miR-16-1 的表达水平降低（0.55±0.23、2.15±0.87、2.08±0.54 和 1.96±0.61）。miR-15a 和 miR-16-1 的下调与较高的 Gleason 评分（P=0.002 和 P=0.006）、较高的肿瘤分期（P=0.001 和 P=0.01）、PCa 转移（P=0.002 和 P=0.025）和淋巴结受累（P=0.02 和 P=0.007）相关。此外，受试者工作特征曲线分析显示，与单独 PSA 相比，联合 miR-15a/miR-16-1 和 PSA 检测可提高 PCa 诊断的敏感性和特异性（分别为 97.1%和 94.3%）。联合血清 miR-15a/miR-16-1 表达和 PSA 水平可作为预测 PCa 诊断和预后的有前途的特异性非侵入性生物标志物，优于单独 PSA。
